A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer

Levi S. Downs, Patricia L. Judson, Peter A. Argenta, Linda F. Carson, Matthew P. Boente

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

To determine toxicity and establish a maximum tolerated dose of outpatient therapy with ifosfamide, paclitaxel, and carboplatin in women with advanced and recurrent cervical cancer. Eligible patients had stage IVB, recurrent or persistent cervical cancer that was not amenable to curative treatment with surgery or radiation therapy. A dose escalation through four dose levels was planned. Dose limiting toxicities were defined as grade 3 or grade 4 hematologic toxicity persistent to day 1 of the next scheduled cycle, grade 2 or higher central neurologic symptoms related to ifosfamide and grade 3 or grade 4 peripheral neuropathy. Twelve patients, aged 29 to 71, received 64 treatments and were evaluable for toxicity. No patient was withdrawn from the study due to toxicity. Two patients had received prior radiation therapy without chemotherapy, and seven patients had received radiation therapy with concurrent chemotherapy. No dose limiting toxicity occurred at dose levels 1 or 2. Three dose reductions occurred at dose level 3 due to neutropenia and thrombocytopenia. The maximum tolerated dose is ifosfamide 2 g/m 2 over 2 h, paclitaxel 175 mg/m 2 over 1 h, and carboplatin at an AUC of 5 over 45 min. Grade 3 or grade 4 neutropenia was seen in 11 subjects. Two patients required growth factor support. Grade 3 or grade 4 anemia was seen in one patient. Grade 3 or grade 4 neuropathy was seen in one patient. Other grade 3 or grade 4 non-hematologic toxicity included muscle weakness, myalgia, cough, and shortness of breath. Combination therapy with ifosfamide 2 g/m 2, paclitaxel 175 mg/m 2, carboplatin AUC = 5 appears to be a safe regimen for the outpatient treatment of women with advanced or recurrent cervical cancer and warrants phase II investigation.

Original languageEnglish (US)
Pages (from-to)347-351
Number of pages5
JournalGynecologic oncology
Volume95
Issue number2
DOIs
StatePublished - Nov 1 2004

Fingerprint

Ifosfamide
Carboplatin
Paclitaxel
Uterine Cervical Neoplasms
Radiotherapy
Maximum Tolerated Dose
Neutropenia
Area Under Curve
Outpatients
Therapeutics
Drug Therapy
Myalgia
Muscle Weakness
Peripheral Nervous System Diseases
Neurologic Manifestations
Cough
Thrombocytopenia
Dyspnea
Anemia
Intercellular Signaling Peptides and Proteins

Keywords

  • Carboplatin
  • Cervical cancer
  • Ifosmide
  • Paclitel

Cite this

A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer. / Downs, Levi S.; Judson, Patricia L.; Argenta, Peter A.; Carson, Linda F.; Boente, Matthew P.

In: Gynecologic oncology, Vol. 95, No. 2, 01.11.2004, p. 347-351.

Research output: Contribution to journalArticle

Downs, Levi S. ; Judson, Patricia L. ; Argenta, Peter A. ; Carson, Linda F. ; Boente, Matthew P. / A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer. In: Gynecologic oncology. 2004 ; Vol. 95, No. 2. pp. 347-351.
@article{40ccd6185aff46f09b6093c3cc7eca06,
title = "A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer",
abstract = "To determine toxicity and establish a maximum tolerated dose of outpatient therapy with ifosfamide, paclitaxel, and carboplatin in women with advanced and recurrent cervical cancer. Eligible patients had stage IVB, recurrent or persistent cervical cancer that was not amenable to curative treatment with surgery or radiation therapy. A dose escalation through four dose levels was planned. Dose limiting toxicities were defined as grade 3 or grade 4 hematologic toxicity persistent to day 1 of the next scheduled cycle, grade 2 or higher central neurologic symptoms related to ifosfamide and grade 3 or grade 4 peripheral neuropathy. Twelve patients, aged 29 to 71, received 64 treatments and were evaluable for toxicity. No patient was withdrawn from the study due to toxicity. Two patients had received prior radiation therapy without chemotherapy, and seven patients had received radiation therapy with concurrent chemotherapy. No dose limiting toxicity occurred at dose levels 1 or 2. Three dose reductions occurred at dose level 3 due to neutropenia and thrombocytopenia. The maximum tolerated dose is ifosfamide 2 g/m 2 over 2 h, paclitaxel 175 mg/m 2 over 1 h, and carboplatin at an AUC of 5 over 45 min. Grade 3 or grade 4 neutropenia was seen in 11 subjects. Two patients required growth factor support. Grade 3 or grade 4 anemia was seen in one patient. Grade 3 or grade 4 neuropathy was seen in one patient. Other grade 3 or grade 4 non-hematologic toxicity included muscle weakness, myalgia, cough, and shortness of breath. Combination therapy with ifosfamide 2 g/m 2, paclitaxel 175 mg/m 2, carboplatin AUC = 5 appears to be a safe regimen for the outpatient treatment of women with advanced or recurrent cervical cancer and warrants phase II investigation.",
keywords = "Carboplatin, Cervical cancer, Ifosmide, Paclitel",
author = "Downs, {Levi S.} and Judson, {Patricia L.} and Argenta, {Peter A.} and Carson, {Linda F.} and Boente, {Matthew P.}",
year = "2004",
month = "11",
day = "1",
doi = "10.1016/j.ygyno.2004.07.037",
language = "English (US)",
volume = "95",
pages = "347--351",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer

AU - Downs, Levi S.

AU - Judson, Patricia L.

AU - Argenta, Peter A.

AU - Carson, Linda F.

AU - Boente, Matthew P.

PY - 2004/11/1

Y1 - 2004/11/1

N2 - To determine toxicity and establish a maximum tolerated dose of outpatient therapy with ifosfamide, paclitaxel, and carboplatin in women with advanced and recurrent cervical cancer. Eligible patients had stage IVB, recurrent or persistent cervical cancer that was not amenable to curative treatment with surgery or radiation therapy. A dose escalation through four dose levels was planned. Dose limiting toxicities were defined as grade 3 or grade 4 hematologic toxicity persistent to day 1 of the next scheduled cycle, grade 2 or higher central neurologic symptoms related to ifosfamide and grade 3 or grade 4 peripheral neuropathy. Twelve patients, aged 29 to 71, received 64 treatments and were evaluable for toxicity. No patient was withdrawn from the study due to toxicity. Two patients had received prior radiation therapy without chemotherapy, and seven patients had received radiation therapy with concurrent chemotherapy. No dose limiting toxicity occurred at dose levels 1 or 2. Three dose reductions occurred at dose level 3 due to neutropenia and thrombocytopenia. The maximum tolerated dose is ifosfamide 2 g/m 2 over 2 h, paclitaxel 175 mg/m 2 over 1 h, and carboplatin at an AUC of 5 over 45 min. Grade 3 or grade 4 neutropenia was seen in 11 subjects. Two patients required growth factor support. Grade 3 or grade 4 anemia was seen in one patient. Grade 3 or grade 4 neuropathy was seen in one patient. Other grade 3 or grade 4 non-hematologic toxicity included muscle weakness, myalgia, cough, and shortness of breath. Combination therapy with ifosfamide 2 g/m 2, paclitaxel 175 mg/m 2, carboplatin AUC = 5 appears to be a safe regimen for the outpatient treatment of women with advanced or recurrent cervical cancer and warrants phase II investigation.

AB - To determine toxicity and establish a maximum tolerated dose of outpatient therapy with ifosfamide, paclitaxel, and carboplatin in women with advanced and recurrent cervical cancer. Eligible patients had stage IVB, recurrent or persistent cervical cancer that was not amenable to curative treatment with surgery or radiation therapy. A dose escalation through four dose levels was planned. Dose limiting toxicities were defined as grade 3 or grade 4 hematologic toxicity persistent to day 1 of the next scheduled cycle, grade 2 or higher central neurologic symptoms related to ifosfamide and grade 3 or grade 4 peripheral neuropathy. Twelve patients, aged 29 to 71, received 64 treatments and were evaluable for toxicity. No patient was withdrawn from the study due to toxicity. Two patients had received prior radiation therapy without chemotherapy, and seven patients had received radiation therapy with concurrent chemotherapy. No dose limiting toxicity occurred at dose levels 1 or 2. Three dose reductions occurred at dose level 3 due to neutropenia and thrombocytopenia. The maximum tolerated dose is ifosfamide 2 g/m 2 over 2 h, paclitaxel 175 mg/m 2 over 1 h, and carboplatin at an AUC of 5 over 45 min. Grade 3 or grade 4 neutropenia was seen in 11 subjects. Two patients required growth factor support. Grade 3 or grade 4 anemia was seen in one patient. Grade 3 or grade 4 neuropathy was seen in one patient. Other grade 3 or grade 4 non-hematologic toxicity included muscle weakness, myalgia, cough, and shortness of breath. Combination therapy with ifosfamide 2 g/m 2, paclitaxel 175 mg/m 2, carboplatin AUC = 5 appears to be a safe regimen for the outpatient treatment of women with advanced or recurrent cervical cancer and warrants phase II investigation.

KW - Carboplatin

KW - Cervical cancer

KW - Ifosmide

KW - Paclitel

UR - http://www.scopus.com/inward/record.url?scp=7444259652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7444259652&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.07.037

DO - 10.1016/j.ygyno.2004.07.037

M3 - Article

C2 - 15491756

AN - SCOPUS:7444259652

VL - 95

SP - 347

EP - 351

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -